Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Climb Bio (CLYM) Liabilities and Shareholders Equity (2020 - 2026)

Climb Bio filings provide 7 years of Liabilities and Shareholders Equity readings, the most recent being $152.4 million for Q1 2026.

  • Quarterly Liabilities and Shareholders Equity fell 24.09% to $152.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $694.8 million through Mar 2026, down 19.78% year-over-year, with the annual reading at $167.7 million for FY2025, 22.77% down from the prior year.
  • Liabilities and Shareholders Equity hit $152.4 million in Q1 2026 for Climb Bio, down from $167.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $226.0 million in Q2 2024 and bottomed at $109.3 million in Q1 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $160.0 million, with a median of $152.4 million recorded in 2026.
  • The largest annual shift saw Liabilities and Shareholders Equity decreased 24.83% in 2023 before it surged 97.1% in 2024.
  • Climb Bio's Liabilities and Shareholders Equity stood at $135.0 million in 2022, then decreased by 18.17% to $110.5 million in 2023, then surged by 96.6% to $217.2 million in 2024, then decreased by 22.77% to $167.7 million in 2025, then fell by 9.16% to $152.4 million in 2026.
  • Per Business Quant, the three most recent readings for CLYM's Liabilities and Shareholders Equity are $152.4 million (Q1 2026), $167.7 million (Q4 2025), and $182.3 million (Q3 2025).